Eventide Asset Management’s Akero Therapeutics AKRO Stock Holding History

Eventide Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-435,293	Closed	-$20.7M	–	270
2025 Q3	$20.7M	Buy	435,293 +235,293	+118%	+$11.4M	0.34%	94
2025 Q2	$10.7M	Sell	200,000 -534	-0.3%	-$24.3K	0.19%	124
2025 Q1	$8.12M	Buy	+200,534	New	+$8.5M	0.16%	131
2023 Q4	–	Sell	-513,876	Closed	-$26M	–	153
2023 Q3	$26M	Buy	513,876 +134,756	+36%	+$6.27M	0.47%	65
2023 Q2	$17.7M	Hold	379,120	–	–	0.3%	91
2023 Q1	$14.5M	Buy	+379,120	New	+$16.9M	0.27%	102

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Eventide Asset Management's AKRO Position: Q4 2025 in Review

Eventide Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 435,293 shares — an estimated $20.7M sold.

Eventide Asset Management first reported a position in AKRO in Q1 2023 and held it in 6 quarters. The position peaked at $26M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Eventide Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Eventide Asset Management sold 435,293 Akero Therapeutics shares in Q4 2025, an estimated $20.7M.
Eventide Asset Management first reported a position in Akero Therapeutics in Q1 2023 and held it in 6 quarters.
Eventide Asset Management's Akero Therapeutics position peaked at $26M in Q3 2023.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.